CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 243 enrolled
Drug / intervention
Fluticasone Furoate/GW642444 Inhalation Powder +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01244984
NCT01244984Phase 3Completed
CompareCT.gov

A Long-term Study to Evaluate the Safety and Tolerability of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and FF Inhalation Powder in Japanese Subjects With Asthma

GlaxoSmithKline·interventional·Posted Nov 22, 2010·Updated Jan 11, 2017

In Brief

A Phase 3 clinical trial evaluating Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder for Asthma. Completed, enrolled 243 participants across 30 sites.

Detailed Summary

The primary purpose of the study is to assess the safety and tolerability of 52-week teatment with fluticasone furoate/GW642444 inhalation powder once-daily and FF inhalation powder once-daily in Japanese adult subjects with asthma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedNov 22, 2010
Enrollment StartJul 1, 2010
Primary CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 15.6 years ago

Interventions

Fluticasone Furoate/GW642444 Inhalation Powderdrug

Fluticasone Furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks

Fluticasone Furoate Inhalation Powderdrug

Fluticasone Furoate inhalation powder inhaled orally once daily for 52 weeks